PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Kollodis BioSciences, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Kollodis BioSciences Announces MAPTrix™ ECM Product Line Extension to Strengthen Product Offering - Kollodis BioSciences announced today the expansion of its ECM product line to address the needs of the emerging stem cell culture market
Kollodis BioSciences Announces MAPTrix™ ECM Product Line Extension to Strengthen Product Offering

 

NewswireToday - /newswire/ - North Andover, MA, United States, 2010/10/04 - Kollodis BioSciences announced today the expansion of its ECM product line to address the needs of the emerging stem cell culture market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Following 2009's successful launch of the MAPTrix™ ECM product line into the general cell culture market, Kollodis BioSciences announced today the expansion of its ECM product line to address the needs of the emerging stem cell culture market.

Construction of a proprietary library (MAPTrix™ ECM Library) comprised of mussel adhesive protein based extracellular matrix mimetics will strengthen Kollodis BioSciences’ market position in the growing stem cell market.

The MAPTrix™ ECM Library is currently comprised peptide mimetics derived from fibronectin, laminin, collagen, vitronectin, nidogen, cadherin, perlecan, and Tenascin- all of which are main ingredients for a basement membrane.

“The MAPTrix™ ECM Library clearly offers a convenient tool for scientists to screen an optimal ECM-derived peptide composition in order to design or create a user-defined cell growth surface. Unlike existing products derived from animal components, MAPTrix™ ECM provides a biochemically well-defined surface for cell cultures”, said Louis M. Scarmoutzos, Ph.D., Chief Executive Officer and President of Kollodis BioSciences.

The offer of ECM-derived peptide compositions to create a customized artificial basement membrane is a global first.

“We believe MAPTrix™ ECM defined substrates provide a breakthrough solution in overcoming several existing market challenges including animal-component free & chemically defined surfaces”, added Louis M. Scarmoutzos, Ph.D., Chief Executive Officer and President of Kollodis BioSciences.

Since MAPTrix™ ECM itself contains a variety of extracellular matrix derived peptides such as RGD or YIGSR, MAPTrix™ ECM based substrates provide a suitable in vivo like environment for cells that require attachment sites. Unlike existing synthetic substrate products, no additional ECM components are required to create an in vivo like environment.

About Kollodis BioSciences, Inc.

Kollodis BioSciences, Inc. (kollodis.com) has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is dedicated to the development, manufacture, and sale of MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix™ platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Kollodis BioSciences, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Kollodis BioSciences Announces MAPTrix™ ECM Product Line Extension to Strengthen Product Offering

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sangjae Lee - Kollodis.com 
617-283-2182 info[.]kollodis.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Kollodis BioSciences, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Kollodis BioSciences, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)